Better Long-Term Buy: This Emerging Player or the Industry Leader?

Group 1: AbbVie Overview - AbbVie is one of the largest pharmaceutical companies globally, particularly recognized for its immunology portfolio, including best-selling therapies like Humira, Skyrizi, and Rinvoq [1][3] - AbbVie has a strong revenue generation capability due to its established product lineup, with Skyrizi and Rinvoq being significant growth drivers that will not lose patent exclusivity until the next decade [4] - AbbVie is noted for its consistent dividend payouts, being classified as a Dividend King, which enhances its appeal as a reliable income stock [4] Group 2: Abivax Overview - Abivax is a clinical-stage biotech company currently without revenue and unprofitable, but it has a promising candidate, obefazimod, in development for ulcerative colitis [5] - Unlike AbbVie's immunosuppressants, obefazimod takes a different approach that may be equally effective without compromising the immune system [5] - The potential of Abivax's obefazimod presents significant upside for investors looking for high-risk, high-reward opportunities in the biotech sector [5]